Dogwood Therapeutics (DWTX) Registration Filing summary

Company overview and business model

• Operates as a pre-revenue, development-stage biopharmaceutical company focused on pain and fatigue-related disorders, with programs in Nav1.7 modulation for pain and combination antiviral therapies for herpes virus-mediated illnesses.

• Lead candidate Halneuron® targets chronic and acute pain, with a Phase 2b study initiated in Q1 2025; antiviral pipeline includes IMC-1 and IMC-2 for fibromyalgia and Long-COVID.

• Incorporated in Delaware, with a history of acquisitions and name changes, most recently acquiring Pharmagesic and rebranding in October 2024.

Financial performance and metrics

• As of May 21, 2025, 1,911,128 shares of common stock were outstanding, with 109 stockholders of record.

• Outstanding warrants for 7,755 shares and options for 81,077 shares, with various exercise prices.

• The company’s financial statements include a going concern warning from its independent auditor.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, R&D, clinical trials, acquisitions, and investments.

• Proceeds may be temporarily invested in short-term, investment-grade, interest-bearing securities.